Phaseline

Targets › SOS1

SOS1 (Son of sevenless homolog 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Promotes the exchange of Ras-bound GDP by GTP. Probably by promoting Ras activation, regulates phosphorylation of MAP kinase MAPK3/ERK1 in response to EGF. Catalytic component of a trimeric complex that participates in transduction of signals from Ras to Rac by promoting the Rac-specific guanine nucleotide exchange factor (GEF) activity (By similarity). (UniProt, Q07889)

Open in Phaseline: the race on SOS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BayerBAY3498264
SOS1 inhibitor
SOS1Phase 1Advanced Solid Tumors Harboring KRAS G12C MutationApr 2027

Conditions

Advanced Solid Tumors Harboring KRAS G12C Mutation (1)

Modalities

small molecule (1)

Companies

Bayer (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.